In 2019, Ardeshna et al. [147] reported the first results of the Alexander trial; subjects with r/r DLBCL were treated with CD19/22-targeted CAR-T cells (Auto-3) and received pembrolizumab 14 days after CAR-T-cell infusion. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.